- /
- Supported exchanges
- / US
- / RGEN.NASDAQ
Repligen Corporation (RGEN NASDAQ) stock market data APIs
Repligen Corporation Financial Data Overview
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Repligen Corporation (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Repligen Corporation data using free add-ons & libraries
Get Repligen Corporation Fundamental Data
Repligen Corporation Fundamental data includes:
- Net Revenue: 785 M
- EBITDA: 144 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-07-28
- EPS/Forecast: 0.45
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Repligen Corporation News
New
Repligen (RGEN) Could Be 10% Below Fair Value On Mixed Q2 Earnings
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. What Repligen's Latest Earnings Mean For Shareholders Repligen (RGEN) is in fo...
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
Immunocore Holdings plc IMCR incurred a loss of 2 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 1 cent per share. In the year-ago quarter, the com...
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Ocugen OCGN reported a second-quarter 2026 loss of 7 cents per share, which was wider than the Zacks Consensus Estimate as well as the year-ago loss of 5 cents. Higher research and development spendin...
Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut
Zoetis, Inc. ZTS delivered second-quarter 2026 adjusted earnings (excluding one-time items) of $1.87 per share, which beat the Zacks Consensus Estimate of $1.84. In the year-ago quarter, the company h...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.